265 related articles for article (PubMed ID: 16505437)
1. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
Cesana GC; DeRaffele G; Cohen S; Moroziewicz D; Mitcham J; Stoutenburg J; Cheung K; Hesdorffer C; Kim-Schulze S; Kaufman HL
J Clin Oncol; 2006 Mar; 24(7):1169-77. PubMed ID: 16505437
[TBL] [Abstract][Full Text] [Related]
2. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
Beyer M; Schultze JL
J Clin Oncol; 2007 Jun; 25(18):2628-30; author reply 2630-2. PubMed ID: 17577047
[No Abstract] [Full Text] [Related]
3. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
Ahmadzadeh M; Rosenberg SA
Blood; 2006 Mar; 107(6):2409-14. PubMed ID: 16304057
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
8. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Maker AV; Attia P; Rosenberg SA
J Immunol; 2005 Dec; 175(11):7746-54. PubMed ID: 16301685
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Siddiqui SA; Frigola X; Bonne-Annee S; Mercader M; Kuntz SM; Krambeck AE; Sengupta S; Dong H; Cheville JC; Lohse CM; Krco CJ; Webster WS; Leibovich BC; Blute ML; Knutson KL; Kwon ED
Clin Cancer Res; 2007 Apr; 13(7):2075-81. PubMed ID: 17404089
[TBL] [Abstract][Full Text] [Related]
12. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
[TBL] [Abstract][Full Text] [Related]
14. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome.
Foureau DM; Amin A; White RL; Anderson W; Jones CP; Sarantou T; McKillop IH; Salo JC
Cancer Immunol Immunother; 2014 Dec; 63(12):1329-40. PubMed ID: 25205170
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).
Atchison E; Eklund J; Martone B; Wang L; Gidron A; Macvicar G; Rademaker A; Goolsby C; Marszalek L; Kozlowski J; Smith N; Kuzel TM
J Immunother; 2010 Sep; 33(7):716-22. PubMed ID: 20664355
[TBL] [Abstract][Full Text] [Related]
17. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.
Griffiths RW; Elkord E; Gilham DE; Ramani V; Clarke N; Stern PL; Hawkins RE
Cancer Immunol Immunother; 2007 Nov; 56(11):1743-53. PubMed ID: 17487490
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.
Seung SK; Curti BD; Crittenden M; Walker E; Coffey T; Siebert JC; Miller W; Payne R; Glenn L; Bageac A; Urba WJ
Sci Transl Med; 2012 Jun; 4(137):137ra74. PubMed ID: 22674552
[TBL] [Abstract][Full Text] [Related]
19. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Camisaschi C; Filipazzi P; Tazzari M; Casati C; Beretta V; Pilla L; Patuzzo R; Maurichi A; Cova A; Maio M; Chiarion-Sileni V; Tragni G; Santinami M; Vergani B; Villa A; Berti E; Umansky L; Beckhove P; Umansky V; Parmiani G; Rivoltini L; Castelli C
Cancer Immunol Immunother; 2013 May; 62(5):897-908. PubMed ID: 23589107
[TBL] [Abstract][Full Text] [Related]
20. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.
Frederiksen KS; Lundsgaard D; Freeman JA; Hughes SD; Holm TL; Skrumsager BK; Petri A; Hansen LT; McArthur GA; Davis ID; Skak K
Cancer Immunol Immunother; 2008 Oct; 57(10):1439-49. PubMed ID: 18286285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
